Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: neuroscience – Page 744

Carbon Free Steel becomes a reality at Volvo and Mercedes Benz

Steelmaking is currently extremely carbon intensive, accounting for about 7% of total global greenhouse gas emissions. As we continue to use ever more steel for new infrastructure around the world, the task of decarbonising the industry is growing ever more urgent. Hydrogen can now perform that task and Volvo has just taken delivery of the first consignment of carbon-free steel. So how is it done, and will it be a gamechanger for the auto industry and wider world?

Video Transcripts available at our website.
http://www.justhaveathink.com.

Help support this channels independence at http://www.patreon.com/justhaveathink.

Or with a donation via Paypal by clicking here.
https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_b…source=url.

You can also help keep my brain ticking over during the long hours of research and editing via the nice folks at BuyMeACoffee.com.
https://www.buymeacoffee.com/justhaveathink.

Interested in mastering and remembering the concepts that I present in my videos? Check out the FREE Dive Deeper mini-courses offered by the Center for Behavior and Climate. These mini-courses teach the main concepts in select JHAT videos and go beyond to help you learn additional scientific or conservation concepts. The courses are great for teachers to use or for individual learning. https://climatechange.behaviordevelopmentsolutions.com/just-have-a-think-jhat.

Continue reading “Carbon Free Steel becomes a reality at Volvo and Mercedes Benz” | >

New evidence shows how viral infections could promote Alzheimer’s

I’m convinced a lot of diseases, MS, parkinsons, alzheimers, most cancers, are the result of bacterial or viral infections.

Building on a growing body of evidence linking viral infections with neurodegenerative disease, a new study published in Nature Communications has demonstrated how certain molecules on the surfaces of viruses can promote the aggregation of toxic proteins associated with diseases such as Alzheimer’s and Parkinson’s.

The idea that microbial infections can trigger neurodegenerative disease is not new. As far back as the 1950s scientists have been postulating ways an acute viral infection can lead to progressive neurological problems years, or even decades, later.

While evidence for this association is certainly growing, the mechanisms by which viral threats can influence the progression of brain diseases are still resolutely hypothetical. A common hypothesis speculates some viral infections may trigger abnormal immune responses that subsequently linger for years, ultimately generating neurological damage associated with some brain diseases.

Human Dementia Study: BioViva Analyzes the Data

I am pleased to share our most recent video on the “Dementia Safety Study” funded by Maximum Life Foundation and run by IHS, in which BioViva did the data analysis. This treatment shows promise for the millions of people who have dementia today. Though not a cure, it is a step in the right direction.

Can gene therapy delay or reverse Alzheimer’s and other dementias?

Want to learn more about BioViva? Visit: https://bioviva-science.com/

Interested in aging tests? https://bioviva-science.com/collections/products.

Facebook https://www.facebook.com/BiovivaScience.
Twitter https://twitter.com/BioVivaScience.
Instagram https://www.instagram.com/biovivascience.
LinkedIn https://www.linkedin.com/in/liz-parrish.

Study Find Links to Genetic Disorders in Walking Patterns

Summary: Researchers have linked Fragile X and SHANK3 deletion syndrome, two disorders associated with autism, to specific microscopic walking patterns.

Source: Rutgers.

Rutgers researchers have linked the genetic disorders Fragile X and SHANK3 deletion syndrome – both linked to autism and health problems – to walking patterns by examining the microscopic movements of those wearing motion-sensored sneakers.

Psilocybin Can Enhance How People Emotionally Connect to Music

Taking psilocybin can affect one’s emotional state when listening to music, according to new research presented earlier this month at the 34th ECNP Congress in Lisbon.

Psilocybin, the active psychedelic component of magic mushrooms, has previously shown great promise when used in therapy settings for the treatment of depression. Many of these clinical trials often make use of selected music playlists to support the subjective psychedelic experience felt by the trial participant.

Now, scientists believe that this action of combining psilocybin with music may result in enhanced emotional processing on behalf of the participant, implying that music should be treated as a more active component of psilocybin therapy.

Mike Graglia, Managing Dir & Co-Founder, SynGAP Research Fund — Collaboration, Transparency, Urgency

Collaboration, transparency & urgency for rare disease research — mike graglia, managing director & co-founder, syngap research fund — SRF.

Mike Graglia is the Managing Director & Co-Founder of the SynGAP Research Fund (SRF — https://www.syngapresearchfund.org/), an organization that he set up in 2018 with his wife Ashley, after their son was diagnosed with a rare neurological disease caused by an insufficiency in SynGAP protein, which causes the life-changing diagnoses of Epilepsy, Autism, sleep disorder and intellectual disability.

The mission of SRF is to improve the quality of life of SynGAP1 patients through the research and development of treatments, therapies and support systems.

Previously, Mike worked at the Emerson Collective, New America Foundation, the Bill and Melinda Gates Foundation, BCG, the World Bank/IFC and the US Peace Corps/Namibia. During his time in Africa he created a small charity to fund girls’ education.

Mike graduated from Gonzaga University with a BS in mathematics. He then attended the Johns Hopkins School of Advanced International Studies (SAIS) and Columbia Business School.

Continue reading “Mike Graglia, Managing Dir & Co-Founder, SynGAP Research Fund — Collaboration, Transparency, Urgency” | >

A diet of essential amino acids could keep dementia at bay, finds study

Protein intake is known to be vital for maintaining brain function in older individuals. Now, using a mouse model of Alzheimer’s disease, researchers have shown that the intake of a specific set of amino acids can inhibit the death of brain cells, protect the connections between them, and reduce inflammation, preserving brain function. Their research suggests that this amino acid combination called Amino LP7 can hinder the development of dementia, including Alzheimer’s disease.

No one knows why some people age worse than others and develop diseases-such as Alzheimer’s, fibrosis, type 2 diabetes or some types of cancer-associated with this aging process

One explanation for this could be the degree of efficiency of each organism’s response to the damage sustained by its cells during its life, which eventually causes them to age. In relation to this, researchers at the Universitat Oberta de Catalunya (UOC) and the University of Leicester (United Kingdom) have developed a new method to remove old cells from tissues, thus slowing down the aging process.

Researchers design antibodies that destroy old cells, slowing down aging

No one knows why some people age worse than others and develop diseases-such as Alzheimer’s, fibrosis, type 2 diabetes or some types of cancer-associated with this aging process. One explanation for this could be the degree of efficiency of each organism’s response to the damage sustained by its cells during its life, which eventually causes them to age. In relation to this, researchers at the Universitat Oberta de Catalunya (UOC) and the University of Leicester (United Kingdom) have developed a new method to remove old cells from tissues, thus slowing down the aging process.

Specifically, they have designed an antibody that acts as a smart bomb able to recognize specific proteins on the surface of these aged or senescent . It then attaches itself to them and releases a drug that removes them without affecting the rest, thus minimizing any potential side effects.

The results of this work, which have been published in Scientific Reports, open the door to the development of effective treatments to delay the progress of age-related diseases and even the aging process itself in the longer term, with the aim of increasing the longevity and, above all, the quality of life of people at this stage of their lives.

Anti-amyloid antibody receives Breakthrough Therapy Designation in US

Roche’s gantenerumab is an anti-amyloid beta antibody developed for subcutaneous administration in Alzheimer’s disease patients.

Roche’s gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD).

/* */